Jing Marantz Biography and Net Worth

Chief Medical Officer of Scholar Rock

Jing L. Marantz joined Scholar Rock November 2022 as Chief Medical Officer, overseeing development and medical affairs. She has over 20 years of experience in the biopharmaceutical industry spanning R&D, business development, and commercial strategy in multiple specialties and rare diseases. Jing currently serves on the board of Arcturus Therapeutics (NASDAQ: ARCT). She was recently EVP and Chief Business Officer of Krystal Biotech, after serving on its board for a year. Prior to Krystal, Jing was Senior Vice President of Medical Affairs at Acceleron Pharma until its acquisition by Merck & Co., Inc. Jing has held leadership positions at Alnylam, Alexion, Biogen, ARIAD, and Millennium Pharmaceuticals across development, medical affairs, and business development. She was a management consultant with Strategic Decisions Group and briefly affiliated with Massachusetts General Hospital following a post-doctoral fellowship at the Dana-Farber Cancer Institute. She received her medical training from Tongji Medical College, a Ph.D. in Biochemistry and Molecular Biology from Medical University of South Carolina, and an MBA from the University of California at Berkeley.

What is Jing L. Marantz's net worth?: The estimated net worth of Jing L. Marantz is at least $2.14 million as of January 16th, 2025. Dr. Marantz owns 67,200 shares of Scholar Rock stock worth more than $2,144,688 as of March 26th. This net worth approximation does not reflect any other investments that Dr. Marantz may own. Learn More about Jing L. Marantz's net worth.
How do I contact Jing L. Marantz?: The corporate mailing address for Dr. Marantz and other Scholar Rock executives is 620 MEMORIAL DRIVE 2ND FLOOR, CAMBRIDGE MA, 02139. Scholar Rock can also be reached via phone at (857) 259-3860 and via email at chu@scholarrock.com. Learn More on Jing L. Marantz's contact information.
Has Jing L. Marantz been buying or selling shares of Scholar Rock?: Over the course of the past ninety days, Jing L. Marantz has sold $249,951.00 in Scholar Rock stock. Most recently, Jing L. Marantz sold 5,655 shares of the business's stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $44.20, for a transaction totalling $249,951.00. Following the completion of the sale, the insider now directly owns 67,200 shares of the company's stock, valued at $2,970,240. Learn More on Jing L. Marantz's trading history.
Who are Scholar Rock's active insiders?: Scholar Rock's insider roster includes Srinivas Akkaraju (Director), Jay Backstrom (President & CEO), Jeffrey Flier (Director), Junlin Ho (General Counsel & Corporate Secretary), Jing Marantz (Chief Medical Officer), Edward Myles (CFO), Caryn Parlavecchio (Insider), Katie Peng (Chief Commercial Officer, Denali Therapeutics), Mo Qatanani (Insider), and Tracey Sacco (Chief Commercial Officer). Learn More on Scholar Rock's active insiders.
Are insiders buying or selling shares of Scholar Rock?: In the last year, insiders at the sold shares 20 times. They sold a total of 2,141,013 shares worth more than $67,818,845.02. The most recent insider tranaction occured on March, 24th when insider Tracey Sacco sold 6,500 shares worth more than $215,020.00. Insiders at Scholar Rock own 19.2% of the company. Learn More about insider trades at Scholar Rock.
Information on this page was last updated on 3/24/2025.

Jing L. Marantz Insider Trading History at Scholar Rock

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
1/16/2025	Sell	5,655	$44.20	$249,951.00	67,200

Jing L. Marantz Buying and Selling Activity at Scholar Rock

Scholar Rock Company Overview

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $31.92

$31.60

$33.25

50 Day Range

MA: $38.40

$33.05

$46.73

2 Week Range

Now: $31.92

$6.76

$46.98

Volume

467,091 shs

Average Volume

1,147,031 shs

Market Capitalization

$3.02 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.59